Literature DB >> 11469729

Chemonucleolysis: the state of the art.

J W Simmons1, E J Nordby, A G Hadjipavlou.   

Abstract

This review presents the history of chemonucleolysis, the techniques, indications, contraindications, and complications. Presenting an historical overview and comparison of success rates with surgical discectomy may provide a fresh understanding of the controversy surrounding chemonucleolysis and establish its efficacy in relation to more invasive treatments. A review of the literature from 1973 through 1998 for chemonucleolysis, open discectomy, and microdiscectomy provided published success rates for these procedures, and a mean rate with standard deviation was determined. In the experience and opinion of the authors, chemonucleolysis remains a viable alternative for patients who have exhausted all conservative means of treatment. Proper patient selection leads to success rates comparable to open discectomy and microdiscectomy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11469729      PMCID: PMC3611493          DOI: 10.1007/s005860000234

Source DB:  PubMed          Journal:  Eur Spine J        ISSN: 0940-6719            Impact factor:   3.134


  4 in total

1.  Sciatica caused by disc herniation: Why is Chymopapain Chemonucleolysis denied to our patients?

Authors:  Douglas Wardlaw
Journal:  Int J Spine Surg       Date:  2016-12-31

Review 2.  A review of current treatment for lumbar disc herniation in children and adolescents.

Authors:  Lei Dang; Zhongjun Liu
Journal:  Eur Spine J       Date:  2009-11-05       Impact factor: 3.134

3.  The Effects of Elgucare on Degenerated Intervertebral Disc-Induced Low Back Pain and Disc Regeneration: A Clinical Trial.

Authors:  Wen-Cheng Lo; Yu Ting Chen; Chen Ching Chen
Journal:  Comput Math Methods Med       Date:  2021-11-08       Impact factor: 2.238

4.  Removal of nucleus pulposus from the intervertebral disc - the use of chymopapain enhances mechanical removal with rongeurs: a laboratory study.

Authors:  Lei Dang; Douglas Wardlaw; David Wl Hukins
Journal:  BMC Musculoskelet Disord       Date:  2007-12-13       Impact factor: 2.362

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.